目的 探讨运脾方联合穴位贴敷对2型糖尿病一级亲属中非糖尿病者的胰岛功能及非高密度脂蛋白/高密度脂蛋白(NHDL-C/HDL-C)、载脂蛋白B/载脂蛋白A-1(ApoB/ApoA-1)的影响。方法 该研究前瞻性选取2019年1月—2020年1月河北省中医院内分泌科...目的 探讨运脾方联合穴位贴敷对2型糖尿病一级亲属中非糖尿病者的胰岛功能及非高密度脂蛋白/高密度脂蛋白(NHDL-C/HDL-C)、载脂蛋白B/载脂蛋白A-1(ApoB/ApoA-1)的影响。方法 该研究前瞻性选取2019年1月—2020年1月河北省中医院内分泌科门诊及住院的2型糖尿病一级亲属中非糖尿病者119例为本次研究对象,采用随机对照的方法分为观察组及对照组。对照组60例患者予以个体化的健康教育,观察组59例患者则在运脾方的基础上加以联合应用穴位贴敷进行治疗,于入组前后分别检测两组患者的血糖及胰岛功能、血压、血脂、血尿酸指标,同时记录体质量、腰围、身体体质量指数(BMI)指数指标,并对NHDL-C/HDL-C、ApoB/ApoA-I指标予以检测分析。结果 干预后两组患者的血糖、C肽以及胰岛素较干预前均有了显著改善,且干预后观察组患者的空腹血糖(FPG)、负荷后1 h血糖(1 hPG)、负荷后2 h血糖(2 hPG)、空腹C肽(FCP)、负荷后1 h C肽(1 h CP)、负荷后2 h C肽(2 h CP)、空腹胰岛素(FIns)、负荷后1 h胰岛素(1 h Ins)及负荷后2 h胰岛素(2 hIns)指标均显著低于对照组(P<0.05);同时,干预后两组患者的胰岛素抵抗指数(HOMA-IR)较干预前也有了显著改善,且干预后观察组患者的HOMA-IR显著低于对照组(P<0.05);干预后两组患者的血脂、血尿酸水平较干预前均有了显著改善,且干预后观察组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)以及血尿酸(UA)水平明显比对照组低,而高密度脂蛋白胆固醇(HDL-C)水平则比对照组高(P<0.05);干预后两组患者的收缩期血压(SBP)、收缩期血压(DBP)、BMI以及腰臀比指数(WHR)水平较干预前有了明显改善,且干预后观察组患者的SBP、DBP、BMI以及WHR水平显著优于对照组(P<0.05);干预后两组患者NHDL-C/HDL-C、ApoB/ApoA-1水平较干预前均显著降低(P<0.05),且干预后观察组NHDL-C/HDL-C、ApoB/ApoA-1水平均显著低于对照组(P<0.05)。结论 通过运脾方联合穴位贴敷治疗2型糖尿病一级亲属中非糖尿病者,可有效降低患者的血糖、血脂及血尿酸水平,改善胰岛功能和NHDL-C/HDL-C、ApoB/ApoA-1水平,进而有效预防糖尿病的发生,值得推广。展开更多
目的:探究2型糖尿病(T2DM)合并代谢相关脂肪性肝病(MAFLD)患者的TG/HDL-C与肝脏脂肪变相关性。方法:选取2023年9月至2024年8月于石家庄市人民医院内分泌科住院接受治疗27~75岁T2DM合并MAFLD患者共186例。根据代表肝脏脂肪变性的严重程...目的:探究2型糖尿病(T2DM)合并代谢相关脂肪性肝病(MAFLD)患者的TG/HDL-C与肝脏脂肪变相关性。方法:选取2023年9月至2024年8月于石家庄市人民医院内分泌科住院接受治疗27~75岁T2DM合并MAFLD患者共186例。根据代表肝脏脂肪变性的严重程度的受控衰减参数(CAP)水平(S0: CAP γ-GGT、TG/HDL-C、CAP均高于非重度脂肪变组,差异均有统计学意义(P γ-GGT、BMI、TG/HDL-C等均呈正相关(r值分别为0.407、0.392、0.422、0.547、0.381、0.433、0.368、0.538、0.568)。(3) 行二元Logistic多因素回归分析得出:TG/HDL-C、LDL-C、BMI、ALT是T2DM合并MAFLD患者肝脏脂肪变的独立危险因素(TG/HDL-C 95%置信区间1.726 (1.238, 2.407),P = 0.001)。(4) 将TG/HDL-C、TG、LDL-C、ALT代入ROC曲线分析,曲线下面积分别为:0.753、0.747、0.609、0.695。其中TG/HDL-C敏感度54.7%,特异度86.3%,TG、TG/HDL-C均能预测T2DM合并MAFLD患者的重度肝脏脂肪变性,但TG/HDL-C预测价值更优(P = 0.000),具有统计学意义。Objective: To investigate the correlation between TG/HDL-C and hepatic steatosis in patients with type 2 diabetes mellitus (T2DM) combined with metabolism-associated fatty liver disease (MAFLD). Methods: A total of 186 patients with T2DM combined with MAFLD aged 27-75 years who were hospitalized in the Department of Endocrinology of Shijiazhuang People’s Hospital from September 2023 to August 2024 were selected. The patients were categorized into 80 cases in the non-severe hepatic steatosis group and 106 cases in the severe hepatic steatosis group according to the level of controlled attenuation parameter (CAP), which represents the severity of hepatic steatosis (S0: CAP γ-GGT, TG/HDL-C, and CAP were higher in the severe steatosis group than those in the non-severe steatosis group, and the differences were statistically significant (P γ-GGT, BMI, and TG/HDL-C (r-values of 0.407, 0.392, 0.422, 0.547, 0.381, 0.433, 0.368, 0.538, respectively, 0.568). (3) Binary logistic multifactorial regression analysis was performed to conclude that TG/HDL-C, LDL-C, BMI, and ALT were independent risk factors for hepatic steatosis in patients with T2DM combined with MAFLD (TG/HDL-C 95% confidence interval 1.726 (1.238, 2.407), P = 0.001). (4) Substituting TG/HDL-C, TG, LDL-C, and ALT into the ROC curve analysis, the areas under the curve were 0.753, 0.747, 0.609, and 0.695, respectively of which the sensitivity of TG/HDL-C was 54.7% and specificity 86.3%, both TG and TG/HDL-C could predict severe hepatic steatosis in patients with T2DM combined with MAFLD, but the predictive value of TG/HDL-C was superior (P = 0.000), which was statistically significant.展开更多
目的探讨各系统检测高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)结果的可比性和适用性或溯源性。方法参照NCCLS批准的EP9-A规程,均采用清除法测...目的探讨各系统检测高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)结果的可比性和适用性或溯源性。方法参照NCCLS批准的EP9-A规程,均采用清除法测定HDL-C、LDL-C,应用5个不同检测系统对伯乐质控品(三个水平)各测定20次,并附带测定低中高浓度的新鲜血清样本各8份。结果伯乐质控血清和24份新鲜血清样本的HDL-C、LDL-C测定经相关性分析,各检测系统间的相关系数为r,其r2≥0.95;各检测系统测定HDL-C、LDL-C的精密度均<1.5%,临床均可接受。以可溯源的检测系统A为目标检测系统,通过临床可接收性能评价,5个系统均未超过T±3%范围。结论5个不同的分析系统测定HDL-C、LDL-C测定结果可比,4个检测系统结果能够溯源到目标系统。展开更多
文摘目的 探讨运脾方联合穴位贴敷对2型糖尿病一级亲属中非糖尿病者的胰岛功能及非高密度脂蛋白/高密度脂蛋白(NHDL-C/HDL-C)、载脂蛋白B/载脂蛋白A-1(ApoB/ApoA-1)的影响。方法 该研究前瞻性选取2019年1月—2020年1月河北省中医院内分泌科门诊及住院的2型糖尿病一级亲属中非糖尿病者119例为本次研究对象,采用随机对照的方法分为观察组及对照组。对照组60例患者予以个体化的健康教育,观察组59例患者则在运脾方的基础上加以联合应用穴位贴敷进行治疗,于入组前后分别检测两组患者的血糖及胰岛功能、血压、血脂、血尿酸指标,同时记录体质量、腰围、身体体质量指数(BMI)指数指标,并对NHDL-C/HDL-C、ApoB/ApoA-I指标予以检测分析。结果 干预后两组患者的血糖、C肽以及胰岛素较干预前均有了显著改善,且干预后观察组患者的空腹血糖(FPG)、负荷后1 h血糖(1 hPG)、负荷后2 h血糖(2 hPG)、空腹C肽(FCP)、负荷后1 h C肽(1 h CP)、负荷后2 h C肽(2 h CP)、空腹胰岛素(FIns)、负荷后1 h胰岛素(1 h Ins)及负荷后2 h胰岛素(2 hIns)指标均显著低于对照组(P<0.05);同时,干预后两组患者的胰岛素抵抗指数(HOMA-IR)较干预前也有了显著改善,且干预后观察组患者的HOMA-IR显著低于对照组(P<0.05);干预后两组患者的血脂、血尿酸水平较干预前均有了显著改善,且干预后观察组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)以及血尿酸(UA)水平明显比对照组低,而高密度脂蛋白胆固醇(HDL-C)水平则比对照组高(P<0.05);干预后两组患者的收缩期血压(SBP)、收缩期血压(DBP)、BMI以及腰臀比指数(WHR)水平较干预前有了明显改善,且干预后观察组患者的SBP、DBP、BMI以及WHR水平显著优于对照组(P<0.05);干预后两组患者NHDL-C/HDL-C、ApoB/ApoA-1水平较干预前均显著降低(P<0.05),且干预后观察组NHDL-C/HDL-C、ApoB/ApoA-1水平均显著低于对照组(P<0.05)。结论 通过运脾方联合穴位贴敷治疗2型糖尿病一级亲属中非糖尿病者,可有效降低患者的血糖、血脂及血尿酸水平,改善胰岛功能和NHDL-C/HDL-C、ApoB/ApoA-1水平,进而有效预防糖尿病的发生,值得推广。
文摘目的:探究2型糖尿病(T2DM)合并代谢相关脂肪性肝病(MAFLD)患者的TG/HDL-C与肝脏脂肪变相关性。方法:选取2023年9月至2024年8月于石家庄市人民医院内分泌科住院接受治疗27~75岁T2DM合并MAFLD患者共186例。根据代表肝脏脂肪变性的严重程度的受控衰减参数(CAP)水平(S0: CAP γ-GGT、TG/HDL-C、CAP均高于非重度脂肪变组,差异均有统计学意义(P γ-GGT、BMI、TG/HDL-C等均呈正相关(r值分别为0.407、0.392、0.422、0.547、0.381、0.433、0.368、0.538、0.568)。(3) 行二元Logistic多因素回归分析得出:TG/HDL-C、LDL-C、BMI、ALT是T2DM合并MAFLD患者肝脏脂肪变的独立危险因素(TG/HDL-C 95%置信区间1.726 (1.238, 2.407),P = 0.001)。(4) 将TG/HDL-C、TG、LDL-C、ALT代入ROC曲线分析,曲线下面积分别为:0.753、0.747、0.609、0.695。其中TG/HDL-C敏感度54.7%,特异度86.3%,TG、TG/HDL-C均能预测T2DM合并MAFLD患者的重度肝脏脂肪变性,但TG/HDL-C预测价值更优(P = 0.000),具有统计学意义。Objective: To investigate the correlation between TG/HDL-C and hepatic steatosis in patients with type 2 diabetes mellitus (T2DM) combined with metabolism-associated fatty liver disease (MAFLD). Methods: A total of 186 patients with T2DM combined with MAFLD aged 27-75 years who were hospitalized in the Department of Endocrinology of Shijiazhuang People’s Hospital from September 2023 to August 2024 were selected. The patients were categorized into 80 cases in the non-severe hepatic steatosis group and 106 cases in the severe hepatic steatosis group according to the level of controlled attenuation parameter (CAP), which represents the severity of hepatic steatosis (S0: CAP γ-GGT, TG/HDL-C, and CAP were higher in the severe steatosis group than those in the non-severe steatosis group, and the differences were statistically significant (P γ-GGT, BMI, and TG/HDL-C (r-values of 0.407, 0.392, 0.422, 0.547, 0.381, 0.433, 0.368, 0.538, respectively, 0.568). (3) Binary logistic multifactorial regression analysis was performed to conclude that TG/HDL-C, LDL-C, BMI, and ALT were independent risk factors for hepatic steatosis in patients with T2DM combined with MAFLD (TG/HDL-C 95% confidence interval 1.726 (1.238, 2.407), P = 0.001). (4) Substituting TG/HDL-C, TG, LDL-C, and ALT into the ROC curve analysis, the areas under the curve were 0.753, 0.747, 0.609, and 0.695, respectively of which the sensitivity of TG/HDL-C was 54.7% and specificity 86.3%, both TG and TG/HDL-C could predict severe hepatic steatosis in patients with T2DM combined with MAFLD, but the predictive value of TG/HDL-C was superior (P = 0.000), which was statistically significant.
文摘目的探讨各系统检测高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)结果的可比性和适用性或溯源性。方法参照NCCLS批准的EP9-A规程,均采用清除法测定HDL-C、LDL-C,应用5个不同检测系统对伯乐质控品(三个水平)各测定20次,并附带测定低中高浓度的新鲜血清样本各8份。结果伯乐质控血清和24份新鲜血清样本的HDL-C、LDL-C测定经相关性分析,各检测系统间的相关系数为r,其r2≥0.95;各检测系统测定HDL-C、LDL-C的精密度均<1.5%,临床均可接受。以可溯源的检测系统A为目标检测系统,通过临床可接收性能评价,5个系统均未超过T±3%范围。结论5个不同的分析系统测定HDL-C、LDL-C测定结果可比,4个检测系统结果能够溯源到目标系统。
